Centessa Pharmaceuticals PLC - CNTA Net earnings per share growth forecast for next year

Corporate company logo of Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals (CNTA) prospects are tied to orexin agonist clinical trials and FDA approval, and the annual EPS growth forecast generated by GURU.Markets currently shows a metric of -9.40. The biotech's results depend on biological factors rather than economic ones; meanwhile, high R&D intensity in the field of rare neurological pathologies paves the way for breakthrough medical discoveries.

Centessa Pharmaceuticals PLC (CNTA): Net earnings per share growth forecast for next year from 07/04/2022 to 07/04/2026

Summary analytical data breakdowns for Centessa Pharmaceuticals PLC (CNTA)

Fundamental company analysis:centessa.com, CNTA
Finished products of Centessa Pharmaceuticals plc

This indicator measures the percentage deviation of the projected earnings per share for the next period from current values, reflecting the consensus estimate of market analysts. On the GURU.Markets platform, shifts in analyst expectations for EPS n+1 growth are critical for Centessa Pharmaceuticals (CNTA), as high R&D expenditures coupled with a revenue deficit make any positive forecasts the primary driver of future capitalization.

Analysis of competing companies